DUBLIN--(BUSINESS WIRE)--Crospon, a medical device developer based in Galway, Ireland has been recognised with the 2012 European Enabling Technology Award for Surgical Imaging Technology by Frost & Sullivan.
The Award is in recognition of Crospon’s pioneering work in the development of a leading edge minimally invasive medical device for monitoring, diagnosis, and therapy in the gastroenterology area. The EndoFLIP® (Endolumenal Functional Lumen Imaging Probe) Imaging System is a revolutionary new technology used for measuring the inner dimensions and functions of critical sphincters and lumens in the gastrointestinal tract and different parts of the body.
The EndoFLIP technology provides a direct measure of mechanical properties, such as the stretching capacity of sphincters and valves in the human body. Previously, this could not be measured directly, and doctors had to depend on indirect measures, such as manometry.
“The revolutionary EndoFLIP technology is a minimally invasive procedure designed to measure the physical properties of the esophageal or any sphincter in the body,” notes Frost & Sullivan Senior Research Analyst Darshana De. “It is a ten-minute procedure and allows for more accurate data compared to traditional manometry. EndoFLIP technology offers both functional and real-time imaging information of the sphincters and is a quick and low-cost option for detecting gastroesophageal reflux disease (GERD).”
Commenting on the Frost & Sullivan recognition, John O’Dea, CEO Crospon said, “Crospon is pleased to have received recognition from Frost & Sullivan for its EndoFLIP surgical imaging technology. The Company continues to build on this platform technology to move into more therapeutic focused areas including the development of smart dilation catheters with integrated imaging for esophageal disorders (EsoFLIP™), and a smart valvuloplasty platform for sizing TAVI (transcatheter aortic valve implantation) valves (TAVIFLIP™).”
Later this week, Crospon’s imaging technology will be featured at “EuroPCR”, Europe’s most important cardiovascular focused annual scientific meeting of the year in Paris.
Speaking in advance of EuroPCR in Paris, John O’Dea said, “TAVI is a key topic amongst cardiologists the world over. Participation and visibility amongst interventional cardiologists at the most important cardiovascular meeting in Europe in 2012 is an important step in the development of this latest product initiative by Crospon.”
Commenting on the Company’s currently released products, John O’Dea added, “We continue to be encouraged by the adoption for our BF-325 gastric band sizing catheter. This novel catheter allows bariatric surgeons fitting, for example, an Allergan LapBand, to make a consistent band adjustment in surgery, so that the patient essentially leaves surgery with their first band adjustment done, thereby starting them on a more aggressive weight loss trajectory. This is for the first time bringing science to the band adjustment process and the early results have been promising”.
Concluding O’Dea said, “Whereas the band has been with us some time, it is only now that technologies like EndoFLIP are emerging to finally address the weak link in the process, namely the trial and error nature of band adjustments”
Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
Ends.